Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

6.510 +0.300 (+4.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
MarketBeat Week in Review – 9/30 - 10/4
A strong jobs report and a temporary settlement of the port strike lifted stocks but inflation and earnings data could set investors up for more volatility 
Via MarketBeat
Topics Economy
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Apogee Enterprises Posts Upbeat Earnings, Joins Frontier Group, JetBlue Airways And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Nike Reports Weak Sales, Joins Lamb Weston And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Here's How Much $100 Invested In Capricor Therapeutics 5 Years Ago Would Be Worth Today
 
Via Benzinga
Deep Dive Into Capricor Therapeutics Stock: Analyst Perspectives (5 Ratings)
 
Via Benzinga
Unveiling 6 Analyst Insights On Capricor Therapeutics
 
Via Benzinga
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
What's Going On With Capricor Therapeutics Stock Friday?
The biotechnology company said deramiocel increased cardiac function based on several different measures. 
Via Benzinga
Expert Ratings For Capricor Therapeutics
 
Via Benzinga
Recap: Capricor Therapeutics Q4 Earnings
 
Via Benzinga
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump
 
Via Benzinga
Topics Stocks
Crude Oil Down Over 1%; Stitch Fix Shares Plummet
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Nvidia, Alibaba, Capricor Therapeutics, TSMC, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Tuesday, major U.S. indices closed higher, with the Dow Jones Industrial Average gaining 0.2% to reach 42,208.22. 
Via Benzinga
Topics Stocks
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Capricor Therapeutics's Earnings Outlook
 
Via Benzinga
Preview: Capricor Therapeutics's Earnings
 
Via Benzinga
Why Capricor Therapeutics Stock Is Soaring Tuesday
Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a biologics license application (BLA) for the full approval of Deramiocel for the... 
Via Benzinga
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and... 
Via Talk Markets
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
Capricor Therapeutics partners with Nippon Shinyaku for the European commercialization of Duchenne muscular dystrophy treatment, deramiocel, with a potential $1.5 billion in milestone payments from... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday?
Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA). 
Via Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday?
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension 
Via Benzinga
CAPR Stock Earnings: Capricor Therapeutics Misses EPS, Misses Revenue for Q1 2024
CAPR stock results show that Capricor Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
FlexShopper And 3 Other Penny Stocks Insiders Are Buying
The Dow Jones closed higher by around 65 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.